Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.
Nivolumab Plus AVD Prolongs PFS in Advanced-Stage Hodgkin Lymphoma
Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.
Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.
Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5